Journal Home Online First Current Issue Archive For Authors Journal Information 中文版

Strategic Study of CAE >> 2017, Volume 19, Issue 2 doi: 10.15302/J-SSCAE-2017.02.016

Strategic Research on the Industrial Development of Innovative Technology in Cell Technology-Related Regenerative Medicine in China

1. Chinese PLA General Hospital, Beijing 100853, China;

2. Academy of Chinese PLA Military Medical Sciences, Beijing 100850, China;

3. Medical Library of Chinese PLA, Beijing 100039, China;

4. Bone Tissue Bank Branch, Chinese Pharmaceutical and Biotechnology Association, Beijing 100022, China

Funding project:中国工程院咨询项目“细胞技术等再生医学类创新型医疗技术产业发展战略研究”(2013-XZ-11) Received: 2016-12-22 Revised: 2017-03-20 Available online: 2017-05-03 10:07:27.000

Next Previous

Abstract

The innovative medical technology industry of regenerative medicine has shown huge economic potential and development prospects both at home and abroad in the last decade. After describing the current situation of industrial development in innovative technology in cell-technology-related regenerative medicine, we investigate, sort, and analyze related policies and regulations, management systems, and existing problems in the United States, the European Union, Japan, Australia, and other developed countries. On this basis, we study the current development situation, governmental regulation policies, and management mechanism of this industry in China. Next, we analyze and summarize the industry development trend, characteristics, and existing problems. Finally, based on experts’ advice and opinions on breaking through the bottleneck of industrial development, we suggest that it is imperative for us to strive to develop the innovative technology industry of cell-technology-related regenerative medicine in China.

References

[ 1 ] Yang Z M. Re-recognition of regenerative medicine [J]. Chinese Journal of Reparative and Reconstructive Surgery, 2010(2): 129–132. Chinese. link1

[ 2 ] Ji M. The inventory of the international approved stem cells prod-ucts [EB/OL]. (2012-09-18) [2016-11-29]. http://www.bioon. com/biopharm/529943.shtml. Chinese. link1

[ 3 ] Chen T, Wu X H, Jiang H Y,et al. Analysis of American stem cell research policies [J]. China Basic Science, 2010, 12(6): 49–53. Chinese. link1

[ 4 ] Chen T, Qian W Q. Comparative analysis of stem cell research and industry development between China and foreign countries [J]. Forum on Science and Technology in China, 2011, 10(10): 150–153, 160. Chinese. link1

[ 5 ] Jiang H J, Sun R J, Pei D Q, et al. Stem cells and regenerative medicine play an important role in the layout for medical science [J]. Bulletin of Chinese Academy of Sciences, 2011, 26(2): 174–178. Chinese. link1

[ 6 ] Huang X. Calling for new therapy methods of the liver regenera-tive medicine [N]. Chinese Science Daily, 2014-09-30(04).

[ 7 ] Xu Y, Wang L, He J, et al. Prevalence and control of diabetes in Chinese adult [J]. The Journal of the American Medical Associa-tion, 2013, 310(9): 948–958. link1

[ 8 ] BioValley. Xu Xiaochun: The drama is yet to come in terms of the stem cells industry development [EB/OL]. (2014-06-18) [2016-11- 29]. http://www.bioon.com/master/talent/597945.shtml. Chinese. link1

[ 9 ] Huang Q. The fact-finding of the stem cells found it is similar to the “gambling” in the ward bed [EB/OL]. (2007-09-19) [2016-11-29]. http://news.xinmin.cn/domestic/zonghe/2007/09/19/895568.html. Chinese. link1

[10] Cyranoski D. China’s stem-cell rules go unheeded [J]. Nature, 2012, 484(7393):149–150.

Related Research